Ascendia

  MARKET NEWS

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Frontera Therapeutics Doses First Patient in a Trial of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Cytovation Announces First Patient Dosed in Phase 2a Study Investigating CyPep-1 Monotherapy in Advanced Melanoma Refractory to Checkpoint Inhibitors
Akari Therapeutics Announces Preclinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy
Nexcella Enters US GMP Manufacturing Agreement to Expand Ongoing Phase 1b/2 Clinical Trial 
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Plas-Tech is a full-service medical device manufacturing company. To better support the drug delivery and biotech markets, we created Equinox Medical as a subsidiary of Plas-Tech Engineering. Together they provide value at every step of the way that enables our customers to benefit from higher quality products with leading edge design for manufacturing, assembly, tooling engineering and polymer materials expertise. With over 30 years of expertise in medical manufacturing our capabilities have proven to be advantageous for our customers in the medical device industry as well as other related industries that require difficult to manufacture products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS

Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS

Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….

First Subject Dosed in Small Pharma’s First-in-Human Phase 1 Clinical Trial

First Subject Dosed in Small Pharma’s First-in-Human Phase 1 Clinical Trial

Phase 1 study will compare two routes of SPL028 administration; intravenous and intramuscular….

VYNE Therapeutics Announces Positive Results from Phase 1a Single & Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor

VYNE Therapeutics Announces Positive Results from Phase 1a Single & Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor

VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo…..

BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer

BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer

BioXcel Therapeutics, Inc. recently announced full data from its Phase 2a trial of BXCL701, the company’s investigational, oral innate immune activator, in combination with….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

WHITEPAPER - Maintaining Sustainable Business Practices During the Energy & Supply Crisis

WHITEPAPER - Maintaining Sustainable Business Practices During the Energy & Supply Crisis

By: Thomas Otto, Managing Director, Vetter

As we come to the end of another year, our global economy faces many significant challenges. Recently, a colleague asked me, “As a biopharma executive, which of today’s major issues are the ones that …

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 1 – Drug Delivery
March 8 – Parenteral Contract Manufacturing